MedTrace Logo

Berberine Supplementation, Sprint Interval Training, and Immune Function Study

NCT07480018 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-07

No results posted yet for this study

Summary

The purpose of this clinical trial is to investigate the effects of a 2-week intervention involving berberine supplementation or sprint training in isolation as well as berberine combined with sprint training on well-being, anaerobic power, and monocyte number and function in individuals experiencing mild mental health challenges. The main questions it aims to answer are:

* Does short-term berberine use or sprint training improve measures of mental health, psychological wellbeing, fatigue, and sleep quality?
* Does short-term berberine use or sprint training improve measures of anaerobic power generation?
* Does short-term berberine use or sprint training improve circulating biomarkers of inflammation?
* Does short-term berberine use or sprint training improve monocyte number, function, and cytokine production?

Conditions

  • Berberine
  • Sprint Training
  • Wellbeing
  • Anaerobic Power
  • Inflammation Biomarkers
  • Monocyte Function

Interventions

DIETARY_SUPPLEMENT

Berberine

Consumption of a commercially-available Berberine supplement at a dosage of 500mg, Three times per day with meals, for a total dosage of 1500mg/day.

OTHER

Placebo

Consumption of placebo capsules composed of rice flour at a dosing of 3 capsules per day with meals.

OTHER

Sprint Interval Training

Multiple sets of maximal effort 30 second sprints, inter spaced with 4 minutes of rest/active recovery, on the cycle ergometer over the course of 6 sessions during the 2-Week intervention. Resistance for each set is calculated at 7.5% of the body mass of the participant. Sets for each session are as follows: (1) 4 Sets, (2) 5 Sets, (3) 6 Sets, (4) 6 Sets, (5) 7 Sets, (6) 4 Sets.

Sponsors & Collaborators

  • University of Northern Colorado

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-05-01
Completion
2026-06-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07480018 on ClinicalTrials.gov